JP2014529612A5 - - Google Patents

Download PDF

Info

Publication number
JP2014529612A5
JP2014529612A5 JP2014527345A JP2014527345A JP2014529612A5 JP 2014529612 A5 JP2014529612 A5 JP 2014529612A5 JP 2014527345 A JP2014527345 A JP 2014527345A JP 2014527345 A JP2014527345 A JP 2014527345A JP 2014529612 A5 JP2014529612 A5 JP 2014529612A5
Authority
JP
Japan
Prior art keywords
carbonyl
phenyl
sulfonamide
propane
quinoxaline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014527345A
Other languages
English (en)
Japanese (ja)
Other versions
JP6002223B2 (ja
JP2014529612A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/052390 external-priority patent/WO2013032951A1/en
Publication of JP2014529612A publication Critical patent/JP2014529612A/ja
Publication of JP2014529612A5 publication Critical patent/JP2014529612A5/ja
Application granted granted Critical
Publication of JP6002223B2 publication Critical patent/JP6002223B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014527345A 2011-08-26 2012-08-24 特定の化学的実体、組成物、および方法 Active JP6002223B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161528033P 2011-08-26 2011-08-26
US61/528,033 2011-08-26
US201161528151P 2011-08-27 2011-08-27
US61/528,151 2011-08-27
PCT/US2012/052390 WO2013032951A1 (en) 2011-08-26 2012-08-24 Certain chemical entities, compositions, and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016171707A Division JP6250116B2 (ja) 2011-08-26 2016-09-02 特定の化学的実体、組成物、および方法

Publications (3)

Publication Number Publication Date
JP2014529612A JP2014529612A (ja) 2014-11-13
JP2014529612A5 true JP2014529612A5 (https=) 2015-10-15
JP6002223B2 JP6002223B2 (ja) 2016-10-05

Family

ID=47744575

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014527345A Active JP6002223B2 (ja) 2011-08-26 2012-08-24 特定の化学的実体、組成物、および方法
JP2016171707A Active JP6250116B2 (ja) 2011-08-26 2016-09-02 特定の化学的実体、組成物、および方法
JP2017223745A Pending JP2018027981A (ja) 2011-08-26 2017-11-21 特定の化学的実体、組成物、および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016171707A Active JP6250116B2 (ja) 2011-08-26 2016-09-02 特定の化学的実体、組成物、および方法
JP2017223745A Pending JP2018027981A (ja) 2011-08-26 2017-11-21 特定の化学的実体、組成物、および方法

Country Status (9)

Country Link
US (5) US9295671B2 (https=)
EP (1) EP2747767B8 (https=)
JP (3) JP6002223B2 (https=)
CN (2) CN107245056A (https=)
AU (1) AU2012300317B2 (https=)
CA (1) CA2846574C (https=)
ES (1) ES2725790T3 (https=)
IL (1) IL231168B (https=)
WO (1) WO2013032951A1 (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
CA2846574C (en) 2011-08-26 2020-07-07 Neupharma, Inc. Quinoxaline sulfonamide derivates for use as kinase inhibitors
CN108794411B (zh) * 2011-09-14 2022-06-07 润新生物公司 某些化学实体、组合物及方法
US9249110B2 (en) 2011-09-21 2016-02-02 Neupharma, Inc. Substituted quinoxalines as B-raf kinase inhibitors
US9249111B2 (en) 2011-09-30 2016-02-02 Neupharma, Inc. Substituted quinoxalines as B-RAF kinase inhibitors
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
EP2806874B1 (en) 2012-01-25 2017-11-15 Neupharma, Inc. Quinoxaline-oxy-phenyl derivatives as kinase inhibitors
JP6378171B2 (ja) 2012-04-24 2018-08-22 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Dna−pk阻害剤
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
EP2897618B1 (en) 2012-09-24 2021-11-17 Neupharma, Inc. Certain chemical entities, compositions, and methods
US9725421B2 (en) 2012-11-12 2017-08-08 Neupharma, Inc. Substituted quinoxalines as B-raf kinase inhibitors
SI3527563T1 (sl) 2013-03-12 2022-01-31 Vertex Pharmaceuticals Incorporated Inhibitorji DNA-PK
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
AU2014308616B2 (en) 2013-08-23 2018-12-06 Neupharma, Inc. Certain chemical entities, compositions, and methods
TWI665195B (zh) * 2013-09-13 2019-07-11 半導體能源研究所股份有限公司 二苯并[f,h]喹啉衍生物、二苯并[f,h]喹啉衍生物的合成方法、發光元件、發光裝置、電子裝置以及照明設備
RU2675270C2 (ru) 2013-10-17 2018-12-18 Вертекс Фармасьютикалз Инкорпорейтед Сокристаллы и содержащие их фармацевтические композиции
JP6752715B2 (ja) 2014-03-26 2020-09-09 アステックス、セラピューティックス、リミテッドAstex Therapeutics Limited 組合せ
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
MX373150B (es) 2014-03-26 2020-04-21 Astex Therapeutics Ltd Combinaciones de un inhibidor del factor de crecimiento de fibroblasto (fgfr) y un inhibidor del receptor del factor de crecimiento 1 similar a insulina (igf1r).
MX385110B (es) * 2014-07-16 2025-03-11 Dev Ct Biotechnology Compuestos de quinoxalina, método para preparar los mismos y uso de los mismos.
TWI719960B (zh) 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
AU2016328693B2 (en) 2015-09-23 2021-03-11 Janssen Pharmaceutica Nv Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
DK3353177T3 (da) 2015-09-23 2020-08-24 Janssen Pharmaceutica Nv Tricykliske heterocykler til behandling af cancer
CN109843858B (zh) * 2016-08-15 2023-05-05 润新生物公司 某些化学实体、组合物及方法
RU2758669C2 (ru) 2016-09-27 2021-11-01 Вертекс Фармасьютикалз Инкорпорейтед Способ лечения рака с применением сочетания днк-поражающих агентов и ингибиторов днк-пк
US10695296B2 (en) * 2017-07-14 2020-06-30 Asana Biosciences, Llc Formulations, methods, kit, and dosage forms for improved stability of an active pharmaceutical ingredient
CA3089678A1 (en) 2018-01-31 2019-08-08 Heparegenix Gmbh Protein kinase mkk4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
SG11202007492XA (en) * 2018-02-08 2020-09-29 Neupharma Inc Certain chemical entities, compositions, and methods
WO2019243315A1 (en) 2018-06-21 2019-12-26 Heparegenix Gmbh Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
US11912701B2 (en) 2018-07-16 2024-02-27 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
US10986841B2 (en) 2018-11-06 2021-04-27 The Clorox Company Bleach compositions
AU2021207236A1 (en) 2020-01-15 2022-08-11 Heparegenix Gmbh 3-benzoyl-1h-pyrrolo[2,3-b]pyridine derivatives as MKK4 inhibitors for treating liver diseases
US11845916B2 (en) 2020-06-24 2023-12-19 The Clorox Company Burstable sporicidal cleaning wipe system containing stabilized hypochlorite
EP4255434A4 (en) * 2020-12-02 2024-10-23 Neupharma, Inc. CERTAIN CHEMICALS, COMPOSITIONS AND PROCESSES
US11728962B2 (en) 2021-12-13 2023-08-15 Xilinx, Inc. Multi-phase clock signal generation circuitry

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464533A (en) 1982-11-08 1984-08-07 Ppg Industries, Inc. Herbicidally active quinoline or quinoxaline benzoate derivatives
IL73152A0 (en) 1983-10-05 1985-01-31 Basf Ag Cyclohexenol derivatives and their use as herbicides
GB2189238A (en) 1986-04-15 1987-10-21 Shell Int Research Heterocyclic phenyl ether compounds
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
CN1087725C (zh) 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
BR9707495A (pt) 1996-02-13 1999-07-27 Zeneca Ltd Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
US6291455B1 (en) 1996-03-05 2001-09-18 Zeneca Limited 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
EP1020453B1 (en) 1997-09-01 2004-05-19 Kyorin Pharmaceutical Co., Ltd. 6,7-asymmetrically disubstituted quinoxalinecarboxylic acid derivatives, addition salts thereof, and processes for the preparation of both
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
SK288365B6 (sk) 1999-02-10 2016-07-01 Astrazeneca Ab Medziprodukty pre chinazolínové deriváty ako inhibítory angiogenézy
NZ522074A (en) 2000-05-31 2004-06-25 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
IL153484A0 (en) 2000-07-07 2003-07-06 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors
CN1255392C (zh) 2000-07-07 2006-05-10 安吉奥金尼药品有限公司 作为血管生成抑制剂的秋水仙醇衍生物
JP2004513134A (ja) 2000-10-12 2004-04-30 メルク エンド カムパニー インコーポレーテッド Hivインテグラーゼ阻害薬として有用なアザ−およびポリアザ−ナフタレニルケトン類
IL139380A0 (en) 2000-10-31 2001-11-25 Prochon Biotech Ltd Active variants of fibroblast growth factor
US7034026B2 (en) 2001-04-10 2006-04-25 Merck & Co., Inc. Inhibitors of Akt activity
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
UA80171C2 (en) 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
CN101044121A (zh) * 2003-02-10 2007-09-26 霍夫曼-拉罗奇有限公司 4-氨基嘧啶-5-酮
CN1882345A (zh) * 2003-10-16 2006-12-20 希龙公司 作为raf激酶抑制剂以治疗癌症的2,6-二取代的喹唑啉、喹喔啉、喹啉和异喹啉
DE102004028862A1 (de) * 2004-06-15 2005-12-29 Merck Patent Gmbh 3-Aminoindazole
WO2006040568A1 (en) * 2004-10-15 2006-04-20 Astrazeneca Ab Quinoxalines as b raf inhibitors
ES2395952T3 (es) * 2005-03-16 2013-02-18 Toyama Chemical Co., Ltd. Nuevo derivado del ácido antranílico o una sal del mismo
GB0509227D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
CN102206216B (zh) 2005-06-22 2014-11-12 普莱希科公司 作为蛋白质激酶抑制剂的吡咯并[2,3-b]吡啶衍生物
US7749530B2 (en) 2005-07-13 2010-07-06 Allergan, Inc. Kinase inhibitors
BRPI0617162B8 (pt) * 2005-10-07 2021-05-25 Exelixis Inc compostos inibidores de fosfatidilinositol 3-quinase composições farmacêuticas que os contem e métodos de uso dos mesmos
PE20081581A1 (es) 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
WO2008124582A1 (en) * 2007-04-05 2008-10-16 Smithkline Beecham Corporation Renin inhibitors
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン,インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
EP2181987B9 (en) 2007-08-23 2014-09-03 Takeda Pharmaceutical Company Limited 2-Carbonylaminobenzothiazoles and their use for the prophylaxis and treatment of cancer
EP2065381A1 (de) 2007-10-18 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP Antagonisten
AU2008337286B2 (en) 2007-12-19 2014-08-07 Cancer Research Technology Limited Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
SI2947072T1 (sl) 2008-03-17 2017-03-31 Ambit Biosciences Corporation 1-(3-(6,7-dimetoksikinazolin-4-iloksi)fenil)-3-(5-1,1,1-trifluoro-2- metilpropan-2-il)izoksazol-3-il)urea kot modulator raf kinaze pri zdravljenju rakavih bolezni
US20100197688A1 (en) 2008-05-29 2010-08-05 Nantermet Philippe G Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
US8110576B2 (en) 2008-06-10 2012-02-07 Plexxikon Inc. Substituted pyrrolo[2,3b]pyrazines and methods for treatment of raf protein kinase-mediated indications
WO2010111527A1 (en) 2009-03-26 2010-09-30 Plexxikon, Inc. Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use
TW201041888A (en) * 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
US20130018033A1 (en) * 2009-08-28 2013-01-17 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
CN101693723B (zh) * 2009-10-22 2012-09-05 浙江大学 间三烷氧基苯基二烷基膦四氟硼酸盐及其合成和应用
WO2011068187A1 (ja) 2009-12-04 2011-06-09 第一三共株式会社 キナゾリン誘導体
WO2011147764A1 (en) 2010-05-28 2011-12-01 N.V. Organon Thieno (2, 3b) pyrazine compounds as b - raf inhibitors
DE102010027215B4 (de) 2010-07-15 2013-09-05 Continental Automotive Gmbh Verfahren und Steuergerät zum Steuern einer Brennkraftmaschine
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
US9493503B2 (en) 2011-02-02 2016-11-15 Neupharma, Inc. Certain chemical entities, compositions, and methods
WO2012118492A1 (en) * 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors
CA2846574C (en) 2011-08-26 2020-07-07 Neupharma, Inc. Quinoxaline sulfonamide derivates for use as kinase inhibitors
CN108794411B (zh) 2011-09-14 2022-06-07 润新生物公司 某些化学实体、组合物及方法
US9249110B2 (en) 2011-09-21 2016-02-02 Neupharma, Inc. Substituted quinoxalines as B-raf kinase inhibitors
US9249111B2 (en) 2011-09-30 2016-02-02 Neupharma, Inc. Substituted quinoxalines as B-RAF kinase inhibitors
EP2806874B1 (en) 2012-01-25 2017-11-15 Neupharma, Inc. Quinoxaline-oxy-phenyl derivatives as kinase inhibitors
EP2897618B1 (en) 2012-09-24 2021-11-17 Neupharma, Inc. Certain chemical entities, compositions, and methods
US9725421B2 (en) 2012-11-12 2017-08-08 Neupharma, Inc. Substituted quinoxalines as B-raf kinase inhibitors

Similar Documents

Publication Publication Date Title
JP2014529612A5 (https=)
JP2014530194A5 (https=)
Marshall et al. An update on the nitrogen heterocycle compositions and properties of US FDA-approved pharmaceuticals (2013–2023)
Cox et al. Kinesin Spindle Protein (KSP) Inhibitors. 9. Discovery of (2 S)-4-(2, 5-Difluorophenyl)-N-[(3 R, 4 S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2, 5-dihydro-1 H-pyrrole-1-carboxamide (MK-0731) for the Treatment of Taxane-Refractory Cancer
DK2646025T3 (en) Use of sigma ligands for pain in bone cancer
AU2006257645B2 (en) Substituted arylpyrazoles as parasiticidal agents
Gelman Androgen receptor activation in castration-recurrent prostate cancer: the role of Src-family and Ack1 tyrosine kinases
TW202144351A (zh) Cdk抑制劑
JP2016503009A5 (https=)
CL2020002371A1 (es) Proceso de preparación de dos derivados de 4-{[(2s)-2-{4-[5-cloro-2-(1h-1,2,3-triazol-1-il)fenil]-5-metoxi-2-oxopiridin-1(2h)-il}butanoil]amino}-2-fluorobenzamida
JP2014501732A5 (https=)
JOP20190186A1 (ar) مركب كينازولين
Araujo et al. Targeting Src signaling in metastatic bone disease
Fukasawa et al. Anti-cancer agent-induced nephrotoxicity
MX2018015353A (es) Usos terapeuticos de un inhibidor de c-raf.
KR20140040770A (ko) 암 치료에 사용하기 위한 cdk4/6 억제제 및 pi3k 억제제를 포함하는 조합 요법
JP2016530274A5 (https=)
WO2007139946A3 (en) Gpcr ligands identified by computational modeling
JP2016530322A5 (https=)
JP2008546751A5 (https=)
JP2018504446A5 (https=)
JP2013529206A5 (https=)
RU2016102149A (ru) Применение сигма-лигандов для предотвращения и лечения боли, связанной с интерстициальным циститом/синдромом раздраженного мочевого пузыря (иц/срмп)
JP2016540811A5 (https=)
JP2014506582A5 (https=)